Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028097 | 0.82 | BRD4 (0.38) | POLBMAPTHPGDTDP1NOS2 | |
| SCHEMBL15651220 | 0.76 | RPS6KA3 (0.31) | — | |
| SCHEMBL15651121 | 0.76 | KDM4E (0.30) | MAPTTDP1GAA | |
| SCHEMBL3692772 | 0.75 | NOS2 (0.41) | JAK2NOS2ALOX15HSD17B10GAA | |
| SCHEMBL30785015 | 0.75 | NOS2 (0.41) | JAK2NOS2ALOX15HSD17B10GAA | |
| SCHEMBL3692774 | 0.75 | NOS2 (0.41) | JAK2NOS2ALOX15HSD17B10GAA | |
| SCHEMBL15291319 | 0.75 | JAK2 (0.39) | JAK2NOS2ALOX15HSD17B10GAA | |
| SCHEMBL15651319 | 0.73 | PARP1 (0.32) | — | |
| SCHEMBL15651321 | 0.73 | PARP1 (0.32) | — | |
| SCHEMBL28129799 | 0.72 | MAOB (0.43) | JAK2MAPTHPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK2 2/4885POLB 1037/4885MAPT 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.